A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism

被引：49

作者：

Hachulla, E

Coghlan, JG

机构：

[1] Ctr Hosp Reg & Univ Lille, Hop Claude Huriez, Serv Med Interne, F-59037 Lille, France

[2] Royal Free Hosp, Dept Cardiol, London NW3 2QG, England

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷 / 09期

关键词：

D O I：

10.1136/ard.2003.017673

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Evidence suggests that endothelin may have a fundamental role in scleroderma pathogenesis, including pulmonary arterial hypertension (PAH)-a leading cause of death in patients with scleroderma. Development of a new class of drug, endothelin receptor antagonists, heralds an improved outlook for patients with scleroderma and related diseases. Heightened vigilance towards early detection of PAH in scleroderma and a multidisciplinary approach to diagnosis and treatment may improve clinical outcomes for these patients.

引用

页码：1009 / 1014

页数：6

共 57 条

[1]

ABUSHAKRA M, 1995, J RHEUMATOL, V22, P2100

[2] PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC-SCLEROSIS (SCLERODERMA) [J].

不详 .

ARTHRITIS AND RHEUMATISM, 1980, 23 (05) :581-590

[3]

[Anonymous], 1998, PRIMARY PULMONARY HY

[4] Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension [J].

Badesch, DB ;

Bodin, F ;

Channick, RN ;

Frost, A ;

Rainisio, M ;

Robbins, IM ;

Roux, S ;

Rubin, LJ ;

Simonneau, G ;

Sitbon, O ;

Tapson, VF .

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2002, 63 (04) :227-246

[5] Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].

Badesch, DB ;

Tapson, VF ;

McGoon, MD ;

Brundage, BH ;

Rubin, LJ ;

Wigley, FM ;

Rich, S ;

Barst, RJ ;

Barrett, PS ;

Kral, KM ;

Jöbsis, MM ;

Loyd, JE ;

Murali, S ;

Frost, A ;

Girgis, R ;

Bourge, RC ;

Ralph, DD ;

Elliott, CG ;

Hill, NS ;

Langleben, D ;

Schilz, RJ ;

McLaughlin, VV ;

Robbins, IM ;

Groves, BM ;

Shapiro, S ;

Medsger, TA ;

Gaine, SP ;

Horn, E ;

Decker, JC ;

Knobil, K .

ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+

[6] Sitaxsentan therapy for pulmonary arterial hypertension [J].

Barst, RJ ;

Langleben, D ;

Frost, A ;

Horn, EM ;

Oudiz, R ;

Shapiro, S ;

McLaughlin, V ;

Hill, N ;

Tapson, VF ;

Robbins, IM ;

Zwicke, D ;

Duncan, B ;

Dixon, RAF ;

Frumkin, LR .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (04) :441-447

[7] Prevalence of pulmonary hypertension in limited and diffuse scleroderma [J].

Battle, RW ;

Davitt, MA ;

Cooper, SM ;

Buckley, LM ;

Leib, ES ;

Beglin, PA ;

Tischler, MD .

CHEST, 1996, 110 (06) :1515-1519

[8]

Black CM, 2003, ARTHRITIS RHEUM, V48, pS454

[9]

Bryan C, 1996, BRIT J RHEUMATOL, V35, P1122

[10] Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study [J].

Channick, RN ;

Simonneau, G ;

Sitbon, O ;

Robbins, IM ;

Frost, A ;

Tapson, VF ;

Badesch, DB ;

Roux, S ;

Rainisio, M ;

Bodin, F ;

Rubin, LJ .

LANCET, 2001, 358 (9288) :1119-1123

← 1 2 3 4 5 6 →